Statistical methods
Statistical analyses were performed using SAS by Sarah Cannon Development Innovations, LLC under the direction of the AstraZeneca Biometrics Group. Descriptive statistics were used to summarize the safety, PK and preliminary antitumor activity data by treatment cohort.Patients who received at least one dose of adavosertib were included in the full analysis set, which was used for safety and efficacy evaluations. The per protocol analysis set was defined as a subset of the full analysis set, excluding subjects having an important protocol deviation, to be used for analyses of efficacy endpoints if appropriate. There were no important protocol deviations; therefore, the patient groups included in the safety and efficacy evaluations were the same.All patients who received at least one adavosertib dose and provided at least one PK sample were included in the PK analysis.